Wei Mai Medical Secures Tens of Millions in Series A Funding, Setting a New Benchmark in Digital Vital Signs Management

VCBeat has exclusively learned that Wismed (Beijing) Intelligent Technology Co., Ltd. (“Wismed Medical”) has completed a Series A financing round worth tens of millions of yuan. This round was solely invested by the Xiamen ITG Industrial Fund, managed by Guoxing Investment. The proceeds will be primarily used to advance product R&D and upgrades, strengthen academic promotion, and build out sales systems and channels. Meanwhile, Wismed Medical will continue to deepen its position as the leading brand in perioperative temperature management and consolidate its market status as the top brand in digital vital signs management.

Seizing this opportunity, Wismed will engage in deep business cooperation with Zhonghong Pulin Medical Products Co., Ltd. (hereinafter referred to as "Zhonghong Medical"), including sharing sales channels, integrating cross-disciplinary technologies, and jointly building both brands. Zhonghong Medical is a holding subsidiary of Xiamen ITG Group, a Fortune Global 500 company, and is listed on the ChiNext board (stock code: 300981). It has been recognized by the State-owned Assets Supervision and Administration Commission of the State Council as a "World-Class Specialized, Refined, Differential, and Innovative Demonstration Enterprise."

Wismed is a high-tech enterprise group engaged in the R&D, production, and sales of innovative high-end medical devices and healthcare services. It focuses on the digital management of patients' vital signs and provides clinicians with vital signs monitoring solutions tailored to diverse clinical scenarios.

Headquartered in Beijing, Wismed operates with dedicated R&D, production, marketing, and management centers. Since its establishment in 2014, the company has grown to a team of over 100 employees. Its core R&D team boasts multidisciplinary and cross-sector industry experience, with the majority hailing from leading organizations such as prestigious research institutes, Mindray Medical, and Huawei.Under the team's leadership, the company has cumulatively obtained more than 100 patents, over 20 software copyrights, and 12 medical device registration certificates.

Through this round of financing, Wismed will deepen its strategic partnership with Zhonghong Medical, fully leveraging and sharing their respective advantages in market presence, talent, and technology. This collaboration will accelerate the further iteration of Wismed’s technological products toward intelligence and digitalization, driving a significant leap forward in both its product offerings and business model.

Leveraging the brand influence of its listed company status and Wismed’s advanced technological products, both parties will achieve shared sales channels and value creation, jointly expanding the broader market for vital signs monitoring and health management.

Furthermore, Zhonghong Medical operates six production bases and six R&D platforms across China. Leveraging their respective multi-center strategic layouts nationwide, both parties will engage in interdisciplinary technological exchange, integration, and continuous innovation. By establishing a brand consortium, they aim to deliver digital, real-time, intelligent, and automated vital signs management solutions, thereby helping hospitals and patients achieve better medical outcomes, service efficiency, and quality of care.

In terms of innovation advantages, Wismed has largely completed the development of three core technology platforms: multi-frequency time-division multiplexing wireless technology, ultra-high-precision data restoration and reconstruction technology, and edge-cloud collaborative technology based on edge computing. The company has established two product lines—digital temperature management solutions and digital vital signs management solutions—providing wearable digital vital signs management solutions for various scenarios to advance the modernization of medical services.

First, digital solutions for perioperative temperature management mainly consist of three components: wireless temperature sensors, active warming systems, and digital quality control software.

Wireless Wearable Temperature Sensor

Photo provided by the interviewee

The integration of wireless temperature sensors with active warming systems achieves closed-loop management of temperature monitoring and thermal regulation, while also digitizing perioperative temperature data. Building on this digital foundation, digital quality control software can leverage big data algorithms and artificial intelligence to digitally extract temperature-related metrics for anesthesia quality control systems, aligning with China’s 2023 “Overall Layout Plan for the Construction of Digital China.”

Body temperature is one of the five vital signs of human life. Maintaining a stable body temperature is essential for ensuring normal metabolism and physiological activities. According to publicly available data, a 1°C drop in body temperature can lead to an approximately 12% decrease in basal metabolic rate and a roughly 30% reduction in immune function.

As clinical and home settings increasingly recognize the value of continuous temperature monitoring, digital temperature management solutions are expanding their application scenarios, driven by superior product performance and positive clinical feedback. Reportedly, this solution has successfully extended beyond the operating room and is poised to become the preferred choice for continuous temperature monitoring in hospital wards and home care settings.

Wismed, grounded in serious medicine and targeting the broader consumer healthcare market, is redefining the temperature management industry and unlocking its development potential.

Digital Vital Signs Management Solution is Wismed’s second product line. Built upon Wismed’s self-developed mobile multi-parameter patient monitors and leveraging the data acquisition, transmission, and sharing capabilities of wearable monitors, this solution centers on the digitalization of continuous vital signs. It establishes a complete data and information flow of vital signs throughout the course of disease, thereby delivering digital vital signs solutions tailored to diverse clinical scenarios.

Multi-parameter Wireless Monitor

Photo provided by the interviewee

Digital vital signs solutions can also be integrated with specific clinical scenarios to enable a variety of intelligent and scalable applications and solutions.

Currently, Wismed’s implemented scenario-based solutions include the Painless Diagnosis and Treatment Mobile Monitoring Solution, the Digital Stroke Center Solution, and the Cardiovascular Disease Management Solution. These solutions enable departments such as Anesthesiology, Cardiology, Rehabilitation Centers, Ambulance Services, Emergency Departments, Surgery, and Geriatrics to conduct continuous vital signs monitoring and to build and apply vital signs big data.

In the post-pandemic era, China’s patient monitor market is characterized by high brand concentration, representing a “red ocean” landscape populated by both international and domestic giants. However, driven by deepening population aging and supportive policies, demand for monitoring devices continues to rise steadily. To identify blue-ocean opportunities within this red-ocean market, it is essential to first gain a thorough understanding of clinical needs.

Having been established for nearly a decade, Wismed has faced deeply entrenched competitors. Instead of engaging in price wars or promotional discounting, the company has remained committed to developing only innovative products and those addressing strong clinical demands. All its R&D efforts are patient-centric, grounded in clinical efficacy and safety, and driven by technological innovation, thereby building a product portfolio that truly meets clinical needs. This strategic focus has been the key development logic enabling Wismed to stand out in the competitive landscape.

According to reports, Wismed’s digital solutions have been deployed in nearly 500 hospitals across 17 provinces and municipalities, and its products have gained recognition from numerous large Grade A tertiary hospitals that maintain exceptionally high standards for medical quality and healthcare services.Used by the Top 3 Hospitals in Every Province and Municipality. In recent years, Wismed's annual sales growth rate has been around 100%.

Many stages of medical device research and development rely on close collaboration between clinicians and medical engineering experts. Wismed is also deepening its partnerships with major hospitals, strengthening innovative clinical application research, and accelerating the development of digital medical devices.

For example, the company collaborated with Xuanwu Hospital of Capital Medical University to develop a digital stroke center solution and with the Chinese People's Liberation Army General Hospital to create a cardiovascular disease management solution. These achievements from medical-engineering collaborations will facilitate the dissemination of tertiary hospital-level solutions to primary healthcare institutions, addressing the urgent need of patients with cardiovascular diseases, stroke, and other conditions for access to high-quality medical resources close to home, thereby advancing the "Healthy China 2030" initiative.

In addition to the deep integration of medicine and engineering, Wismed has attracted numerous industry-leading talents in fields such as artificial intelligence and cloud computing, and is conducting explorations into cutting-edge technologies, driven by the continuous iteration and upgrading of its technological products. Wismed has established in-depth collaborations with research institutions and universities, including the Chinese Academy of Sciences, Xidian University, Beijing Normal University, and Northwestern Polytechnical University.

Looking ahead, Wismed, with the goal of becoming a “leader in digital smart healthcare ecosystems,” will develop more intelligent upgrade products for various medical scenarios. For instance, it will expand its digital stroke center solutions to encompass full-course disease management for neurological disorders, comprehensively building a digital and smart healthcare ecosystem across all clinical settings, thereby establishing itself as an industry-leading provider of innovative smart healthcare solutions.

Yin Shichang, Founder and CEO of Wismed, stated:Wismed has established scenario-based solutions for multi-vital sign monitoring that integrate hardware and software. Wismed positions itself as a leader in the digital smart healthcare ecosystem. Several key terms define this vision. “Digital” refers to Wismed’s core technologies, including industrial wireless transmission, high-fidelity reconstruction based on data refactoring, edge collaboration, and machine learning. These technologies constitute Wismed’s foundation and core competency. Leveraging this foundation, Wismed addresses critical clinical needs, such as quality control and the enhancement of diagnostic and therapeutic capabilities, by building integrated hardware-software scenario-based solutions for clinical settings. This is what is meant by “smart healthcare.”Beyond meeting clinical demands, smart healthcare enables Wismed to establish connections with both patients and physicians through these solutions. These connections allow physicians to recognize the performance and features of Wismed’s products, while helping patients understand that Wismed operates within the realm of serious medical care. With this connectivity in place, Wismed can extend its medical services beyond the hospital setting, such as providing post-diagnosis management for stroke and digital therapeutics for temperature regulation. This constitutes Wismed’s so-called ecosystem covering pre-hospital, in-hospital, and out-of-hospital patient care.

Tan Wen, Deputy General Manager of Guoxing Investment, stated:Wismed possesses technological advantages in wireless vital signs monitoring and the capability for innovative upgrades, particularly in non-invasive core temperature monitoring. It has resolved the technical challenges associated with perioperative core temperature monitoring—a critical unmet clinical need that is scarce within the medical industry—thereby providing the company with a core competitive advantage for future development. Wismed’s innovative technologies have substantial market potential in the field of anesthesiology, offering high growth prospects. By aligning with clinical needs and continuously expanding and upgrading its offerings, the company is creating digital, scenario-based solutions for vital signs monitoring. We look forward to Wismed leveraging its technological strengths and commitment to continuous innovation to become a leader and frontrunner in smart healthcare, addressing unmet clinical needs and benefiting patients.

Yang Hao, President of Zhonghong Medical, stated:Zhonghong Medical’s Innovation Incubation Division is currently making significant strides in expanding its business within the anesthesia and critical care sectors. After nearly a year of communication and collaboration, Zhonghong Medical’s business team and Wismed have reached a broad consensus on the market prospects of Wismed’s temperature monitoring products and other offerings. Deep strategic cooperation is a natural progression, representing a powerful alliance between two industry leaders. Zhonghong Medical boasts strong channel advantages, with a domestic sales team of over 100 professionals covering more than 3,000 tiered hospitals across China. Wismed demonstrates outstanding R&D capabilities, closely aligning with policy directives and addressing clinical pain points for medical staff and patients based on real-world clinical needs. The synergy from this partnership will yield results far greater than the sum of its parts (1+1>>2). Building on this foundation, both parties will explore further collaboration in the research, production, and sales of new products, paving the way for additional opportunities and deeper engagement in the future.

The company operates four fund management platforms registered with the Asset Management Association of China (AMAC). Its portfolio comprises 13 funds of various types, including venture capital (VC), private equity (PE), fund of funds (FOF), and corporate venture capital (CVC), with total assets under management (AUM) reaching RMB 14 billion. Headquartered in Xiamen, the company adopts a research-driven investment approach, focusing on emerging industries such as next-generation information technology, new energy, new materials, and healthcare.

Guoxing Investment actively invests in innovative enterprises within the healthcare and wellness sector, leveraging its platform advantages and resources. It has invested in projects including Northcore Life, Saikesaisi, Sinobond, and Zhishan Biology, accumulating extensive industrial resources in the medical field. Adhering to the values of “Integrity, Momentum, Professionalism, and Win-Win Cooperation,” Guoxing Investment is committed to becoming the most trusted long-term partner for enterprises, jointly creating substantial returns.

Zhonghong Medical (Stock Code: 300981) is a National High-Tech Enterprise, selected as one of the 200 “World-Class Specialized, Refined, Differential, and Innovative Demonstration Enterprises” by the State-owned Assets Supervision and Administration Commission of the State Council, and ranked among the Top 50 Listed Chinese Medical Device Companies. The Company is engaged in the research and development, production, and sales of medical consumables and equipment, including high-quality disposable health protection products and sterile medical devices. It operates three business divisions—Health Protection, Safe Infusion, and Innovation Incubation—and has established six production bases and six R&D platforms across China, striving to become a globally leading integrated supplier of medical health products and services.